SignalSci tracks every biotech licensing deal, pharma partnership, and academic tech transfer — in real time. Built for investors and founders who need an edge, not a $32,000/year seat.
Upfronts, milestones, royalties, and territorial rights for every biotech licensing deal. Updated as deals close, not weeks later.
Track which pharmas are acquiring what, where they're spending, and which therapeutic areas are hot. Understand the market before your next board meeting.
TTO disclosures, university spinouts, and early-stage licensing from the labs where the next generation of assets originate. The pipeline DealForma ignores.
Not a database you query. A system that watches. Get notified when a deal hits your therapeutic areas, deal size thresholds, or competitor tracking list.
DealForma charges $18,000-$32,000 per seat per year. It's designed for enterprise BD analysts at top-10 pharma companies who need deal comps for partnership negotiations. That's a different product for a different customer.
Founders and investors need deal intelligence — but at a price that makes sense for a 10-person biotech or a small VC fund. And they need it framed as market intelligence, not just deal records.
You'll know about it before it hits the press.